Results of Maruho’s Phase III Study with Chugai’s Nemolizumab for Atopic Dermatitis Published in The New England Journal of Medicine Online

TOKYO, July 9, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that results from a phase III study conducted by Maruho Co., Ltd. investigating nemolizumab in atopic dermatitis patients 13 years of age or older with moderate-to-severe pruritus were published in The New England Journal of Medicine Online. Nemolizumab is an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody created by Chugai. Article: https://www.nejm.org/doi/full/10.1056/NEJMoa1917006. Press release by Maruho issued on July 9, 2020: Maruho Announces New England Journal of Medicine Publication of Results from Phase 3 Clinical Study (Comparative Study) in Japan of Nemolizumab for the Treatment of Atopic Dermatitis https://www.maruho.co.jp/english/release/nek5p40000005vzg-att/20200709_pr_eng.pdf [Note] Nemolizumab Achieves Primary Endpoint in Phase 3 Clinical Study (Comparative Study) in Japan for the Treatment of Atopic Dermatitis (Press release by Maruho issued on Apr 18, 2029) https://www.maruho.co.jp/english/release/nek5p40000004lm8-att/20190418_pr_eng.pdf Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331), a Novel Biologic in the Skin Disease Area for the Japanese Market (Press release issued on Sep 28, 2016) https://www.chugai-pharm.co.jp/english/news/detail/20160928150000_121.html

The release as fetched from its publisher. chugai-pharm.co.jp ↗